Capital International Investors’s Rubius Therapeutics, Inc RUBY Stock Holding History

Capital International Investors’s Portfolio RUBY Stock Details RUBY Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q2	–	Sell	-416,396	Closed	-$2.29M	–	468
2022 Q1	$2.29M	Hold	416,396	–	–	﹤0.01%	440
2021 Q4	$4.03M	Hold	416,396	–	–	﹤0.01%	441
2021 Q3	$7.45M	Hold	416,396	–	–	﹤0.01%	430
2021 Q2	$10.2M	Hold	416,396	–	–	﹤0.01%	428
2021 Q1	$11M	Hold	416,396	–	–	﹤0.01%	412
2020 Q4	$3.16M	Hold	416,396	–	–	﹤0.01%	428
2020 Q3	$2.09M	Hold	416,396	–	–	﹤0.01%	425
2020 Q2	$2.49M	Hold	416,396	–	–	﹤0.01%	399
2020 Q1	$1.85M	Hold	416,396	–	–	﹤0.01%	383
2019 Q4	$3.96M	Hold	416,396	–	–	﹤0.01%	374
2019 Q3	$3.27M	Hold	416,396	–	–	﹤0.01%	385
2019 Q2	$6.55M	Hold	416,396	–	–	﹤0.01%	372
2019 Q1	$7.54M	Hold	416,396	–	–	﹤0.01%	360
2018 Q4	$6.09M	Sell	416,396 -170,000	-29%	-$3.1M	﹤0.01%	356
2018 Q3	$12.5M	Buy	+586,396	New	+$13.4M	0.01%	340

Other funds holding RUBY

Flagship Pioneering Cambridge, Massachusetts $1.16B AUM 67.93% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Baillie Gifford & Co Edinburgh, United Kingdom $110B AUM 4.8% 1-Year Est. Return

Artal Group Luxembourg $1.01B AUM 29.84% 1-Year Est. Return

Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

AFM

Abbot Financial Management Andover, Massachusetts $293M AUM 36.12% 1-Year Est. Return

Harbourvest Partners Boston, Massachusetts $101M AUM 38.13% 1-Year Est. Return

Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

Capital International Investors's RUBY Position: Q2 2022 in Review

Capital International Investors sold out of Rubius Therapeutics, Inc (RUBY) in Q2 2022, closing a stake of 416,396 shares — an estimated $2.29M sold.

Capital International Investors first reported a position in RUBY in Q3 2018 and held it in 15 quarters. The position peaked at $12.5M in Q3 2018. 72 funds tracked by Wall St. Rank hold RUBY as of Q2 2022.

Capital International Investors reported no remaining Rubius Therapeutics, Inc position as of Q2 2022 after selling out during the quarter.
Capital International Investors sold 416,396 Rubius Therapeutics, Inc shares in Q2 2022, an estimated $2.29M.
Capital International Investors first reported a position in Rubius Therapeutics, Inc in Q3 2018 and held it in 15 quarters.
Capital International Investors's Rubius Therapeutics, Inc position peaked at $12.5M in Q3 2018.
72 funds tracked by Wall St. Rank held Rubius Therapeutics, Inc as of Q2 2022.

Based on Capital International Investors's 13F filing for Q2 2022, filed 15 Aug 2022.